Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « inhibitors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
inhibitoren < inhibitors < inhibitory  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 41.
[0-20] [0 - 20][0 - 41][20-40]
Ident.Authors (with country if any)Title
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000042 (2020) Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000083 (2020) Wen Zhang [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Fengchun Zhang [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Taisheng Li [République populaire de Chine] ; Zhengyin Liu [République populaire de Chine] ; Jinglan Wang [République populaire de Chine] ; Yan Qin [République populaire de Chine] ; Xuan Zhang [République populaire de Chine] ; Xiaowei Yan [République populaire de Chine] ; Xiaofeng Zeng [République populaire de Chine] ; Shuyang Zhang [République populaire de Chine]The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
000087 (2020) Wanhai Ke ; Li Zhang ; Yan DaiThe role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000109 (2020) Eric Toussirot [France]The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition
000122 (2020) Timothy M. Smith ; Anuj Tharakan ; Rebecca K. MartinTargeting ADAM10 in Cancer and Autoimmunity
000141 (2020) Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000158 (2020) Qingyun Zhu [République populaire de Chine] ; Yingying Shen [République populaire de Chine] ; Xiguang Chen [République populaire de Chine] ; Jun He [République populaire de Chine] ; Jianghua Liu [République populaire de Chine] ; Xuyu Zu [République populaire de Chine]Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells
000170 (2020) Renba Liang ; Xishan Chen ; Li Chen ; Fangzhu Wan ; Kaihua Chen ; Yongchu Sun ; Xiaodong ZhuSTAT3 signaling in ovarian cancer: a potential therapeutic target
000183 (2020) Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]Risk of infection associated with new therapies for lymphoproliferative syndromes.
000187 (2020) Durga Prasanna Misra [Inde] ; Vikas Agarwal [Inde] ; Armen Yuri Gasparyan ; Olena Zimba [Ukraine]Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
000195 (2020) Linyu Geng [République populaire de Chine, États-Unis] ; Xiaojun Tang [République populaire de Chine] ; Shiying Wang [République populaire de Chine] ; Yue Sun [République populaire de Chine] ; Dandan Wang [République populaire de Chine] ; Betty P. Tsao [États-Unis] ; Xuebing Feng [République populaire de Chine] ; Lingyun Sun [République populaire de Chine]Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus
000197 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000203 (2020) Jae-A Park [Corée du Sud] ; Min-Young Lee [Corée du Sud] ; Jin Hyun Nam [États-Unis] ; Ju-Young Shin [Corée du Sud] ; Robert Wood [Royaume-Uni] ; Tim Holbrook [Royaume-Uni] ; Sun-Hong Kwon [Corée du Sud]Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea.
000206 (2020) Christos Koutsianas ; Konstantinos Thomas ; Dimitrios VassilopoulosReactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
000208 (2020) Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000256 (2020) Francesco Bennardo [Italie] ; Caterina Buffone [Italie] ; Amerigo Giudice [Italie]New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.
000260 (2020) Ruksana HudaNew Approaches to Targeting B Cells for Myasthenia Gravis Therapy
000269 (2020) Jose Manuel Sánchez-Maldonado [Espagne] ; Manuel Martínez-Bueno [Espagne] ; Helena Canhão [Portugal] ; Rob Ter Horst [Pays-Bas] ; Sonia Mu Oz-Pe A [Espagne] ; Ana Mo Iz-Díez [Espagne] ; Ana Rodríguez-Ramos [Espagne] ; Alejandro Escudero [Espagne] ; Signe B. Sorensen [Danemark] ; Merete L. Hetland [Danemark] ; Miguel A. Ferrer [Espagne] ; Bente Glintborg [Danemark] ; Ileana Filipescu [Roumanie] ; Eva Pérez-Pampin [Espagne] ; Pablo Conesa-Zamora [Espagne] ; Antonio García [Espagne] ; Alfons Den Broeder [Pays-Bas] ; Salvatore De Vita [Italie] ; Svend Erik Hove Jacobsen [Danemark] ; Eduardo Collantes [Espagne] ; Luca Quartuccio [Italie] ; Mihai G. Netea [Pays-Bas, Allemagne] ; Yang Li [Pays-Bas] ; João E. Fonseca [Portugal] ; Manuel Jurado [Espagne] ; Miguel Ngel L Pez-Nevot [Espagne] ; Marieke J. H. Coenen [Pays-Bas] ; Vibeke Andersen [Danemark] ; Rafael Cáliz [Espagne] ; Juan Sainz [Espagne]NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium
000324 (2020) Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon]Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
000344 (2020) Sadaf Atiqi [Pays-Bas] ; Femke Hooijberg [Pays-Bas] ; Floris C. Loeff [Pays-Bas] ; Theo Rispens [Pays-Bas] ; Gerrit J. Wolbink [Pays-Bas]Immunogenicity of TNF-Inhibitors

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "inhibitors" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "inhibitors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    inhibitors
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021